6 ideas
Pisano shows that despite decades of scientific breakthroughs, the biotech sector as a whole has produced modest, uneven profits and few sustainably profitable firms. The gap between science and business performance is the book's central puzzle.
Pisano argues biotech's business model mismatches its science on three counts: profound and persistent uncertainty, knowledge spread across many disciplines that must be integrated, and cumulative learning that the market structure disrupts. The Silicon Valley venture model was imported without fixing these.
The dominant model splits drug discovery across specialized firms trading intellectual property, but Pisano contends drug R&D requires integrated organizations that hold and accumulate knowledge over long horizons. Fragmentation defeats the cumulative learning that hard problems demand.
Pisano generalizes from biotech to argue that turning any new science into a business requires an institutional architecture matched to the science's uncertainty and learning needs. Copying the model from another industry, like software, systematically misfires.
Because drug development spans a decade or more with high failure rates, public and venture capital markets that reward short-term signals price and manage biotech poorly. The financing structure fights the biology.
Pisano defines a category of firm whose competitive advantage rests on advancing fundamental science, not just applying it. Such firms need governance, financing and organization built for open-ended discovery rather than predictable engineering.